Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Trastuzumab or Lapatinib
DRUG
2 trials
Sponsors
Azienda Ospedaliera Ordine Mauriziano di Torino
, GlaxoSmithKline
Conditions
Cancer
Metastatic Breast Cancer
Phase 2
Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
NCT00842998
Azienda Ospedaliera Ordine Mauriziano di Torino
Metastatic Breast Cancer
Start: 2009-02-28
End: 2011-12-31
Target: 120
Updated: 2009-06-26
Unknown Phase
Brain Metastasis in Breast Cancer Patients
Completed
NCT01077648
GlaxoSmithKline
Cancer
Start: 2010-02-28
End: 2013-08-31
Updated: 2014-05-26
Related Papers
Abstract P1-08-23: Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
Cancer Research
2013-12-15
2 citations
Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer
Molecular Oncology
2013-09-13
42 citations